Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Disoproxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | POLG | P54098 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Disoproxil SCHEMBL16237284 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL985120 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL3234290 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL2670560 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL29356301 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL18190782 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL40021 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL3113154 | 0.97 | FAP (0.94) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL1560984 | 0.97 | FAP (0.94) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL497677 | 0.95 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4299563-A2 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | Japan Tobacco Inc. (JP) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022040435-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20210171556-A1 | METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOF | AMPAC FINE CHEMICALS LLC | 2021-06-10 | — | — | US | disclosed |
| US-20210094977-A1 | METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOF | AMPAC FINE CHEMICALS LLC | 2021-04-01 | — | — | US | disclosed |
| WO-2020236952-A1 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2020-11-26 | — | — | WO | disclosed |
| CN-108822149-B | Preparation method of tenofovir alafenamide fumarate key intermediate | 成都苑东生物制药股份有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20200207793-A1 | METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOF | AMPAC FINE CHEMICALS LLC | 2020-07-02 | — | — | US | disclosed |
| US-20200138719-A1 | TENOFOVIR GRANULES | STEERLIFE INDIA PRIVATE LIMITED (IN) | 2020-05-07 | — | — | US | disclosed |
| US-10561614-B2 | Tenofovir granules | STEERLIFE INDIA PRIVATE LIMITED (IN) | 2020-02-18 | — | — | US | disclosed |
| CN-103705478-B | Oral tablet containing tenofovir disoproxil fumarate | 浙江华海药业股份有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-10155007-B2 | Synthesis method for improved tenofovir disoproxil fumarate using ion-exchange resin and method for preparing oral dissolving film form using the same | FIRSON (KR) | 2018-12-18 | — | — | US | disclosed |
| US-20180214378-A1 | TENOFOVIR GRANULES | STEERLIFE INDIA PRIVATE LIMITED (IN) | 2018-08-02 | — | — | US | disclosed |
| EP-3281939-A1 | METHOD OF PRODUCING STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | Japan Tobacco Inc. (JP) | 2018-02-14 | — | — | EP | disclosed |
| US-20170354668-A1 | Synthesis Method For Improved Tenofovir Disoproxil Fumarate Using Ion-Exchange Resin And Method For Preparing Oral Dissolving Film Form Using The Same | FIRSON (KR) | 2017-12-14 | — | — | US | disclosed |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | UNIVERSITY OF MINNESOTA (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010132864-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | INTERMUNE, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094977-A1 | METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOF | DCTD, TYMP, PPIP5K2 | FAP 361/4885CYP3A4 272/4885CYP2D6 754/4885 |
| US-20200207793-A1 | METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOF | DCTD, TYMP, PPIP5K2 | FAP 361/4885CYP3A4 272/4885CYP2D6 754/4885 |
| US-20210171556-A1 | METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOF | DCTD, TYMP, PPIP5K2 | FAP 361/4885CYP3A4 272/4885CYP2D6 754/4885 |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | MMP1, MMP8, CCL11 | FAP 70/4885CYP3A4 3433/4885CYP2D6 4184/4885 |
| US-20170354668-A1 | Synthesis Method For Improved Tenofovir Disoproxil Fumarate Using Ion-Exchange Resin And Method For Preparing Oral Dissolving Film Form Using The Same | DHX36, DHX30, SAMHD1 | FAP 3061/4885CYP3A4 395/4885CYP2D6 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.